Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies

On November 9, 2021 Takara Bio Inc. (Takara Bio), reported that it has decided jointly with Otsuka Pharmaceutical Co., Ltd. (Otsuka), to terminate agreements on co-development and exclusive marketing of the drug candidates oncolytic virus HF10 (development code: TBI-1401, INN: canerpaturev) and CD19 targeted CAR gene therapies (development code: TBI-1501) (Press release, Takara Holdings, NOV 9, 2021, View Source [SID1234611429]).
Takara Bio and Otsuka will continue to co-develop NY-ESO-1・siTCRTM gene therapy product (development code: TBI-1301).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1.Reasons for the termination

Oncolytic virus HF10
Both Takara Bio and Otsuka have discussed development plans for pancreatic cancer and other malignancies after the Phase I clinical trial for pancreatic cancer, however, in consideration of the time required for future development and other factors, two companies have decided to terminate the agreement.

CD19-targeted CAR gene therapies
Both companies have been conducting a Phase I/II trial for adult acute lymphoblastic leukemia, however, in consideration of the lengthy period for clinical development and the competitive landscape, the two companies have decided to terminate the agreement.

2.Details of the termination agreement
Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.

3.Overview of the other party to terminate this agreement

[1] Company name

Otsuka Pharmaceutical Co., Ltd.

[2] Head office

2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan

[3] URL
View Source

4. Schedule
Corporate resolution, date of the termination agreement: November 9, 2021

5. Future Outlook
The impact of the termination of these agreements on the consolidated financial results of the Company for the FY2022 ending March, 2022 will be minor.